TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
September 29, 2020 08:00 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
TCR² Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 12, 2020 06:45 ET
|
TCR2 Therapeutics
- TC-210 patient with partial response confirmed by independent central review and tumor regression improved further from 42% to 75% - Began dosing of TC-110 in the Phase 1/2 trial for patients...
TCR² Therapeutics Announces Pricing of Public Offering of Common Stock
July 28, 2020 20:05 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies...
TCR² Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors
July 26, 2020 17:00 ET
|
TCR2 Therapeutics
- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients - Two RECIST unconfirmed partial responses and two patients with stable disease through six months - Manageable...
TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors
July 24, 2020 16:05 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients...
TCR² Therapeutics to Present at the BMO Prescriptions for Success Healthcare Conference
June 17, 2020 08:00 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR² Therapeutics Hires Key Business Development and Regulatory Affairs Cell Therapy Experts to Support Strategic Objectives
May 27, 2020 08:00 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients...
TCR² Therapeutics to Present Data on PD-1 Switch TRuC Enhancement at American Association for Cancer Research (AACR) Virtual Meeting 2020
May 15, 2020 08:30 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients...
TCR² Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 14, 2020 06:45 ET
|
TCR2 Therapeutics
Continued progress on treatment of TC-210 patients with interim update from Phase 1 portion of Phase 1/2 clinical trial anticipated in mid-2020Continued progress of TC-110 with initiation of leading...
TCR² Therapeutics Announces Veteran Finance Executive Stephen Webster Joins its Board of Directors
May 04, 2020 06:45 ET
|
TCR2 Therapeutics
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients...